INTRODUCTION
============

Astrocytes, glial cells characterized by glial fibrillary acidic protein (GFAP) expression, play a critical role in maintaining a microenvironment that supports neurons and also participate in the formation of the blood-brain barrier [@B001]. Additionally, astrocytes involves in various neural and cognitive functions. During neurodevelopment, gp130-JAK/STAT3 pathways are known as the main pathways involved in astrocytogenesis, during which neural precursor cells (NPCs) differentiate into astrocytes during the prenatal stage [@B002]. Several neurotrophic cytokines, such as ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF), function as gliogenic signals by which NPCs generate astrocytes via the JAK/STAT pathways [@B003].

Moreover, recent studies have established that PACAP, a ligand of the G protein-coupled PAC1 receptor, is able to trigger the differentiation of astrocytes from NPCs via cAMP-dependent signaling pathways [@B004]. However, new insights suggest that PACAP-induced cAMP activates Epac, an exchange protein that is directly activated by cAMP, which acts as a guanine nucleotide exchange factor to activate Rap small GTPase [@B005]. Epac1 is expressed throughout the body, while Epac2 is expressed mainly in the brain, pituitary gland, adrenal gland, and pancreas [@B006], [@B007] and a deficit in Epac2 causes brain dysfunction, such as impairments in memory and social interaction [@B008], [@B009]. Additionally, studies using a global Epac agonist demonstrated that Epac regulates astrocyte differentiation via the transcription factor DREAM during neurodevelopment [@B010].

However, the roles of Epac2 during development remain unknown and whether Epac2 is involved in astrocytogenesis during embryogenesis, as well as the related underlying mechanism, is still unclear. Here, we investigated whether Epac2 regulates astrocyte differentiation in the brain during development, and demonstrate the pathway involved in this process, by using Epac2 global knockout (KO) mice.

RESULTS
=======

Epac2 regulates astrocytogenesis during brain development
---------------------------------------------------------

We examined the expression of NeuN and GFAP as markers of neurons and astrocytes, respectively, in wild-type (WT) and Epac2-KO neonatal mouse brains. At postnatal day 0, cerebral GFAP expression in KO mice was significantly decreased, by approximately 70% as compared to WT mice ([Fig. 1](#F001){ref-type="fig"}A and [1](#F001){ref-type="fig"}B, \*P = 0.000012), but not NeuN expression (Supplementary [Fig. 1](#F001){ref-type="fig"}A), indicating that Epac2-deficiency causes defective astrocytogenesis without changing neuronal expression during brain development.

![GFAP expression is reduced in the neonatal brain of Epac2-knockout (KO) mice. (A, B) Western blot representing GFAP expression in the cerebrum of wild-type (WT) and Epac2-knockout (KO) mice at postnatal day 0. GFAP protein expression was decreased by approximately 70% in Epac2-KO neonatal brain (independent-samples Mann-Whitney U test, \*P = 0.000012; WT = 4, KO = 5 in each trial, trial number = 4). (C-F) Immunohistochemistry images showing GFAP expression in the hippocampal CA field and major forceps of corpus callosum of WT (C and E, respectively) and KO mice (D and F, respectively) at postnatal day 0. The intensity of GFAP immunoreactivity in both the hippocampus and major forceps was lower in KO mice than in WT mice (G, \*P = 0.03 for hippocampus; \*P = 0.04 for major forceps, independent-samples *t*-test; WT mice = 4, slices = 8; KO mice = 4, slices = 8). Scale bars = 200 μm.](BMB-49-128-g001){#F001}

We then inspected two major types of astrocytes, protoplasmic and fibrous astrocytes, in the brains of WT and Epac2-KO mice using immunohistochemistry at postnatal day 0. Epac2-KO neonatal mice showed less intense GFAP immunoreactivity in both protoplasmic (gray matter) ([Fig. 1](#F001){ref-type="fig"}D and [1](#F001){ref-type="fig"}G, \*P = 0.03) and fibrous (white matter) astrocytes ([Fig. 1](#F001){ref-type="fig"}F and [1](#F001){ref-type="fig"}G, \*P = 0.04) in the cornu ammonis (CA) of the hippocampus and the major forceps of the corpus callosum, respectively, than WT mice ([Fig. 1](#F001){ref-type="fig"}C, hippocampus; [Fig. 1](#F001){ref-type="fig"}E, major forceps). However, hippocampal NeuN expression did not differ between the two genotypes (Supplementary [Fig. 1](#F001){ref-type="fig"}B). These data implied that Epac2 gene deficiency in the developing brain causes overall astrocytogenesis defects, rather than neurogenesis defects.

Epac2 is involved in PACAP-induced astrocytogenesis
---------------------------------------------------

Next, we investigated whether a lack of Epac2 affects astrocyte differentiation from neural precursor cells (NPCs) *in vitro*. Without basic fibroblast growth factor (bFGF), NPCs usually differentiate into astrocytes by day 4 in culture, in the absence of inducing factors. We compared the ability of cortical NPCs from WT and KO mice to generate GFAP-expressing astrocytes at day 0 (DAT0) in the presence of bFGF ([Fig. 2](#F002){ref-type="fig"}A), and at day 4 (DAT4) after removing bFGF ([Fig. 2](#F002){ref-type="fig"}B). In contrast to WT NPCs, Epac2-KO NPCs were unable to differentiate into GFAP-immunopositive astrocytes by DAT4 after removing bFGF from the culture media ([Fig. 2](#F002){ref-type="fig"}B) as judged by the number of GFAP-immunopositive cells ([Fig. 2](#F002){ref-type="fig"}E, ^\#^P = 0.0001) and GFAP intensity ([Fig. 2](#F002){ref-type="fig"}F, ^\#^P = 0.0066). We then investigated the Epac2-regulated upstream signaling involved in astrocytogenesis. CNTF induces astrocyte differentiation [@B003] and activates the MAPK and JAK/STAT pathway. Therefore, we investigated whether CNTF contributes to astrocytic differentiation of NPCs in Epac2-KO mice by adding CNTF into the culture media. Both WT and KO mice presented more GFAP-immunopositive cells ([Fig. 2](#F002){ref-type="fig"}C and [2](#F002){ref-type="fig"}E, \*P = 0.003) and much stronger GFAP intensity in immunopositive cells ([Fig. 2](#F002){ref-type="fig"}C and [2](#F002){ref-type="fig"}F, \*P = 0.024) at DAT4 after CNTF treatment compared to those seen in non-treated WT NPCs ([Fig. 2](#F002){ref-type="fig"}B). However, CNTF-induced astrocyte differentiation did not differ between the WT and KO NPCs ([Fig. 2](#F002){ref-type="fig"}C, [2](#F002){ref-type="fig"}E, and [2](#F002){ref-type="fig"}F), implying that the absence of Epac2 did not affect CNTF-activated astrocytogenesis from NPCs.

![Epac2 is involved in PACAP-induced astrocytogenesis. (A) GFAP immunolabeling of neural precursor cells (NPCs) at day 0 (DAT0). NPCs from neither wild-type (WT) nor Epac2-knockout (KO) mice expressed GFAP at DAT0. (B) WT NPCs remarkably differentiated into astrocytes when cultured in bFGF-free media for 4 days (at DAT4), but KO NPCs showed much lower GFAP immunoreactivity than WT NPCs. (C) CNTF (50 ng/ml) induced differentiation of NPCs of both genotypes into astrocytes. (D) WT NPCs incubated in PACAP (100 nM)-treated media for 4 days expressed GFAP, but KO NPCs did not display astrocytic differentiation. (E) Ratio of GFAP-immunopositive cell number to total NPCs number. KO NPCs did not show GFAP-immunopositive astrocytes by DAT4 in bFGF-free media (^\#^P = 0.0001, independent-samples *t*-test, trial number = 8). Treatment with either CNTF or PACAP increased differentiation of WT NPCs into astrocytes compared to WT NPCs without treatment at DAT4 (\*P = 0.003 for CNTF, \*P = 0.002 for PACAP, independent-samples *t*-test, trial number in each experiment = 8), but KO NPCs did not induce astrocytic differentiation after PACAP treatment contrast to CNTF treatment (^\#\#^P = 0.0002, independent-samples *t*-test, trial number = 8). (F) GFAP intensity of immunopositive cells. KO NPCs showed much lower intensity in GFAP immunoreactivity compared to WT NPCs at DAT4 in bFGF-free media (^\#^P = 0.0066, independent-samples *t*-test). Treatment with either CNTF or PACAP increased GFAP intensity in WT NPCs compared to WT NPCs without treatment at DAT4 (\*P = 0.024 for CNTF, \*P = 0.007 for PACAP, independent-samples *t*-test), but contrast to CNTF, KO NPCs did not increase GFAP immunoreactivity even after PACAP treatment compared to WT NPCs (^\#\#^P = 0.00004, independent-samples *t*-test). Scale bar = 200 μm.](BMB-49-128-g002){#F002}

Next, we examined the effect of PACAP treatment on astrocyte differentiation in NPCs. Before PACAP treatment, we assessed the expression of the PACAP receptor, PAC1R, in WT NPCs and found that all nestin-immunopositive NPCs expressed PAC1R (Supplementary [Fig. 2](#F002){ref-type="fig"}). In the presence of PACAP, more NPCs from WT mice had differentiated into astrocytes by DAT4 ([Fig. 2](#F002){ref-type="fig"}D), as seen by the number of GFAP- immunopositive cells ([Fig. 2](#F002){ref-type="fig"}E, \*P = 0.002) and the GFAP intensity in the immunopositive cells ([Fig. 2](#F002){ref-type="fig"}F, \*P = 0.007), than in the absence of PACAP ([Fig. 2](#F002){ref-type="fig"}B). Contrary to CNTF, NPCs deficient in Epac2 exhibited markedly lower GFAP-immunopositive signals than did WT NPCs after treatment with PACAP ([Fig. 2](#F002){ref-type="fig"}D) in terms of both GFAP-immunopositive cell number ([Fig. 2](#F002){ref-type="fig"}E, ^\#\#^P = 0.0002) and intensity ([Fig. 2](#F002){ref-type="fig"}F, ^\#\#^P = 0.00004). Thus, a genetic deficiency of Epac2 impairs PACAP-stimulated astrocytic differentiation signaling pathways, but not those stimulated by CNTF.

PACAP regulates the intracellular calcium concentration of NPCs via Epac2 during astrocytogenesis
-------------------------------------------------------------------------------------------------

Finally, we investigated which intermediate mediator of astrocytogenesis is involved in PACAP-Epac2 signaling pathway. In nervous tissue, calcium is involved in synaptic activity [@B011] and in astrocytes in particular, intracellular calcium levels play a key role in GFAP expression [@B010]. We monitored the cytoplasmic calcium levels of NPCs loaded with the fluo-4 AM calcium indicator during astrocytic differentiation that was induced by either PACAP or CNTF. PACAP treatment caused an approximately three-fold increase in the intracellular calcium level as compared to base-line levels in WT NPCs within 1 min after treatment, but not in Epac2-KO NPCs ([Fig. 3](#F003){ref-type="fig"}A and [3](#F003){ref-type="fig"}B), indicating that the PACAP-induced intracellular calcium flux may be mediated by Epac2.

![PACAP regulates intracellular calcium concentration of neural precursor cells via Epac2. (A, B) Wild-type (WT) neural precursor cells (NPCs) treated with PACAP exhibited a three-fold higher concentration of calcium ions than baseline (before treatment), but intracellular calcium levels in Epac2-knockout (KO) NPCs maintained the basal level even after PACAP treatment (independent-samples Mann-Whitney U test, \*P = 0.000054, trial number: WT = 10 and KO = 8). (C, D) CNTF did not influence intracellular calcium levels in NPCs of either genotypes (trial number: WT = 7 and KO = 7). (E, F) PACAP treatment did not induce an increase in the intracellular calcium concentration under calcium-free condition (independent-samples Mann-Whitney U test, \*P = 0.000019, trial number = 15), indicating that increase in calcium concentration is derived from extracellular calcium ion source. The gray bars shown in b, d, and f indicate the duration of PACAP treatment (for 30 s). Scale bar = 50 μm.](BMB-49-128-g003){#F003}

In contrast, calcium levels remained unchanged in NPCs of both WT and KO mice after treatment with CNTF ([Fig. 3](#F003){ref-type="fig"}C and [3](#F003){ref-type="fig"}D), suggesting that the intracellular calcium concentration of NPCs may not be involved in CNTF-induced GFAP expression. Next, we sought the source of the PACAP-induced increases in calcium levels, using WT NPCs in calcium-free culture media. Interestingly, under calcium-free conditions, PACAP treatment did not cause an increment of intracellular calcium level ([Fig. 3](#F003){ref-type="fig"}E and [3](#F003){ref-type="fig"}F). Thus, PACAP-Epac2 signaling increased intracellular calcium concentration through an influx of calcium from extracellular sources, rather than from intracellularly stored calcium ion.

Next, we investigated whether the PACAP-induced intracellular calcium increase is required for astrocytogenesis. PACAP treatment barely induced astrocytogenesis under calcium-free conditions, as compared to calcium-containing conditions ([Fig. 4](#F004){ref-type="fig"}A), indicating that the PACAP-induced increase in intracellular calcium is crucial for astrocytogenesis. We also assessed whether increased intracellular calcium levels trigger astrocytogenesis in Epac2-KO NPCs after PACAP treatment, by applying caffeine to Epac2-KO NPCs, as caffeine increases intracellular calcium levels by inducing calcium release from intracellular stores in mammalian neurons [@B012]. Caffeine treatment (100 μM or 1 mM) of Epac2-KO NPCs induced an intracellular calcium concentration increase in KO NPCs within 1 min ([Fig. 4](#F004){ref-type="fig"}B) and recovered astrocytogenesis in a dose-dependent manner after PACAP treatment, as compared to vehicle application ([Fig. 4](#F004){ref-type="fig"}C).

![Intracellular calcium increase induced by PACAP-Epac2 signaling plays a key role in astrocytogenesis. (A) Wild-type (WT) neural precursor cells (NPCs) treated with PACAP in calcium-containing media showed prominent GFAP expression, whereas WT NPCs treated with PACAP in calcium-free media exhibited markedly lower astrocytic differentiation (trial number = 3). (B) Application of caffeine (100 μM or 1 mM) to Epac2-knockout (KO) NPCs raised the intracellular calcium concentration (trial number = 3). (C) Caffeine-induced increase in intracellular calcium levels by release from intracellular calcium stores recovered PACAP-induced astrocytogenesis in Epac2-KO NPCs in a dose-dependent manner, as compared to vehicle-treated KO NPCs (trial number = 3). Scale bars = 200 μm for A and C; Scale bar = 25 μm for B.](BMB-49-128-g004){#F004}

Therefore, Epac2 is stimulated by PACAP, but not by CNTF, causing an influx of extracellular calcium into NPCs, leading to astrocytic differentiation and GFAP expression. Moreover, our data indicated that astrocytogenesis from NPCs follow two distinct signaling pathways: the PACAP-Epac2-calcium ion pathway and the CNTF signaling pathway.

DISCUSSION
==========

We here investigated the role of Epac2 in astrocyte differentiation during neurodevelopment, although Epac2 is expressed in the cortex, hippocampus, and striatum of adult mouse brain (Supplementary [Fig. 3](#F003){ref-type="fig"}A and [3](#F003){ref-type="fig"}B). We found that Epac2-deficiency impaired PACAP-induced astrocytic differentiation of NPCs without affecting neuronal differentiation, and that an increase in intracellular calcium levels is crucial in the PACAP-Epac2 signaling pathway-induced astrocytogenesis. Previous studies have demonstrated that astrocytogenesis involves the PACAP-Epac signaling pathway [@B010], [@B013]. However, these studies could not differentiate between the role of Epac1 or Epac2, because they used a pan-Epac agonist, although each subtype of Epac has a different functional role in the brain. Our data imply a key role for Epac2 in the increase of intracellular calcium levels during GFAP expression in PACAP-induced astrocytogenesis, but not in CNTF-induced astrocytogenesis. These findings from Epac2-KO mice imply that abnormalities in Epac2 functions could result in dysfunction of astrocytes in the formation of the blood-brain barrier, support of energy metabolism, neurotransmitter-related roles, ion concentration regulation, etc., in nervous tissues [@B001]. This could lead to cognitive dysfunction [@B014], [@B015] or psychiatric disorders [@B016], [@B017].

Although it has been reported that PACAP, as an Epac agonist, regulates differentiation of neural stem cells into astrocytes [@B010], some matters require clarification. First, it is not clear whether the PACAP signaling pathway functions distinctly from the CNTF-JAK/STAT pathway as the main route for astrocyte differentiation. Second, the intermediate signaling molecule in GFAP expression stimulated by PACAP-Epac2 activation remains unidentified. CNTF modulates NPC proliferation, and regulates the astrocytic differentiation of these cells via the JAK/STAT pathway [@B018]. Here, we found that Epac2-deficiency in NPCs did not affect CNTF-induced astrocytic differentiation of NPCs, indicating that intracellular signaling for astrocytogenesis via Epac2 is independent of the CNTF-JAK/STAT pathway.

Cytoplasmic calcium ions in NPCs play pivotal roles in cell proliferation, cell death, and differentiation [@B019], [@B020]. Among factors inducing astrocytogenesis, PACAP has been shown to regulate intracellular calcium levels by mobilizing intracellularly stored calcium and modulating an extracellular calcium influx [@B004], [@B021], as was also supported by our study. Cytoplasmic calcium levels in WT NPCs increased three-fold via an influx of extracellular calcium after PACAP treatment and this increase was crucial to PACAP-induced astrocytogenesis. In contrast to WT NPCs, Epac2-KO NPCs showed no difference in cytoplasmic calcium concentration before and after PACAP treatment. However, caffeine-induced increased intracellular calcium levels rescued PACAP-induced astrocytogenesis in Epac2-KO NPCs. Taken together, these results indicate that, during astrocytic differentiation of NPCs, the PACAP-Epac2-mediated pathway controls calcium influx for GFAP expression. Although further studies are necessary to identify the mechanism underlying the stimulation of calcium influx via PACAP-activated Epac2, it remains possible that Epac2 may regulate whole-cell currents and surface expression of calcium channels by controlling the delivery of calcium channels to the plasma membrane or degradation of calcium channels via the proteasome or lysosome. Furthermore, in the present study we found that CNTF did not mediate intracellular calcium fluctuation during astrocytogenesis. Future studies should ascertain functional differences between the PACAP-mediated pathway and the CNTF-mediated pathway during astrocytogenesis.

This is the first report of the role of Epac2 in regulating differentiation of NPCs into astrocytes induced by PACAP, not by the CNTF-JAK/STAT pathway. These findings will facilitate the development of therapeutic agents targeting astrocytic dysfunction or malformation of gliosis that is observed in many brain disorders, such as dementia and psychiatric disorders.

MATERIALS AND METHODS
=====================

Animals
-------

All experiments and animal protocols were carried out in accordance with the guidelines for the Care and Use of Laboratory Animals of Kyungpook National University, and pain and discomfort to animals were minimized.

The Epac2-KO mouse was generated by placing loxP sites containing a Neo-cassette around a 9.6-kb DNA fragment of exon 3 of mouse *Epac2* [@B008], and the lack of Epac2 expression was confirmed by reverse transcriptase polymerase chain reaction (PCR) analysis using the following three primers: mCG2- I2F, 5\'-CGTCTTACTCTAGAAACGAC-3\', mCG2-E3F, 5\'-TGTTTCGCCATGGGGATATTG-3\', and mCG2-I34R, 5\'-CTGGTGCTCACACCTCGTAC-3\'. The PCR products were a 300-bp single band (KO), a 600-bp single band (WT), or both bands (heterozygote).

Cell culture
------------

Neural stem cells were isolated from the cortexes of mice at embryonic day 17 and were then cultured in the presence of 20 μg/ml bFGF (10018, PeproTech, Rocky Hill, NJ) in DMEM (Gibco, Thermo Fisher, Waltham, MA) with 1X N2 supplement (Gibco, Thermo Fisher, Waltham, MA) for 7 days. Culture media were replaced on alternate days and cells were seeded at a density of 2 × 10^4^ cells/cm^2^ on poly L-lysine coated 13Ø cover glasses, and were acclimated for 24 h before treatment with reagents. For astrocyte differentiation, cells were cultured in DMEM with N2 or calcium-free DMEM (Gibco, Thermo Fisher, Waltham, MA) with N2, which was then replaced with bFGF-free DMEM with N2 and a differentiation factor, such as 100 nM PACAP (A1439, Sigma- Aldrich, St Louis, MO) or 50 ng/ml CNTF (1203158, PeproTech) for 4 days. To assay the intracellular calcium increase in Epac2-KO NPCs, 100 μM or 1 mM caffeine (C0750, Sigma- Aldrich, St Louis, MO) was applied to cells, along with 100 nM PACAP, for 4 days.

Immunocytochemistry
-------------------

Cells were fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) for 20 min at room temperature, and were then permeabilized with 0.1% Triton X-100 for 15 min. Subsequently, cells were incubated in 3% BSA in PBS for 1 h. Pretreated cells were incubated with primary antibodies against GFAP (1 : 1,000 dilution, DAKO, Glostrup, Denmark) polyclonal antibody at 4℃ overnight, after which they were incubated with an Alexa Fluor-conjugated secondary antibody (1:500 dilution, Molecular Probes, Eugene, OR) at room temperature for 1 h. Fluorescence was detected under a laser confocal microscope (Zeiss LSM 5 Exciter, Zeiss, Oberkochen, Germany) [@B022]. GFAP intensity was measured by using Image J 1.47v (<http://imagej.nih.gov/ij>).

Intracellular calcium dynamics measurement
------------------------------------------

Calcium concentration was measured by using the calcium indicator Fluo-4 AM (F-14201, Molecular Probes). Specifically, 5 μM Flou-4 AM in phenol-red-free DMEM with Pluronic F-127 (P-3000MP, Molecular Probes) was added to the cell cultures, and cells incubated at 37℃ for 30 min prior to experiments. In calcium-negative assays, the culture media were replaced by calcium-free DMEM containing Fluo-4 AM. Cells were mounted in the chamber on the temperature- and carbon dioxide- controlled stage of a Nikon Ti-E inverted microscope (Nikon, Tokyo, Japan). Then, a final concentration of 1 μM PACAP, 0.5 μg/ml CNTF, or 100 μM or 1 mM caffeine with PACAP was added to the culture, via a peristaltic pump (EYELA MP3, Tokyo, Japan), and calcium ion levels monitored by time-lapse photography. All systems were controlled by MetaMorph software (Molecular Devices, Sunnyvale, CA).

Preparation of brain tissue
---------------------------

The brains of neonatal mice were dissected for immunohistochemistry. To prepare paraffin sections, the brain tissue was post-fixed with 4% PFA at 4℃ for 48 h before dehydration with 30% sucrose. For western blotting, whole brains of neonatal littermate mice were dissected after decapitation, frozen in liquid nitrogen, and then stored at −80℃ until required.

Immunohistochemistry
--------------------

The mouse brains were coronal-sectioned at a 3-μm thickness and tissues were rehydrated with a series of 100%, 90%, 80%, 70%, and 50% ethanol at room temperature for 30 s, after deparaffinization with xylene for 10 min, twice. After PBS washing and blocking with 4% normal goat serum and re-permeabilization with 0.3% Triton X-100 in PBS for 2 h, tissues were incubated with anti-GFAP (1:1,000 dilution, DAKO) polyclonal antibody, at 4℃ overnight. GFAP immunodetection was performed with the ABC kit (VECTASTAIN Elite ABC Kit, PK-6101, Vector Laboratories, Burlingame, MA) and DAB chromogen (3, 3\'-diaminobenzidine HRP substrate, SK-4100, Vector Laboratories). The slides were covered with Vectamount after dehydration. GFAP intensity was measured by using Image J 1.47v (<http://magej.nih.gov/ij>).

Western blotting
----------------

Western blotting was performed with whole brain lysate homogenized in RIPA buffer including EDTA-free protease inhibitors (Roche, Basel, Switzerland). Thirty micrograms of total protein was loaded into each well of a sodium dodecyl sulfate-polyacrylamide gel and proteins electrophoretically separated under 80V, after which the proteins were transferred to a nitrocellulose membrane. After blocking with 5% skim-milk, the membrane was incubated at 4℃ overnight with anti-GFAP (1:5,000, clone G-A-5; Sigma) monoclonal antibody, or anti-GAPDH (1:5,000 dilutions, Santa Cruz Biotechnology, TX) polyclonal antibody. The blots were visualized using a SuperSignal West Femto Maximum Sensitivity substrate (Thermo Fisher) [@B023]. Data were normalized to GAPDH, using Image J 1.47v (<http://imagej.nih.gov/ij>).

Statistical analysis
--------------------

The data from western blot and intracellular calcium dynamics measurement did not fit a Gaussian distribution and we therefore used the independent-samples Mann-Whitney U test for analysis. The data from immunohistochemistry and immunocytochemistry were analyzed using independent-samples *t*-tests. All of the statistical analyses were conducted with Statistical Package for Social Science v22 (SPSS, IBM, USA). Differences were considered statistically significant at P ＜ 0.05. Error bars indicate the standard error of the mean (S.E.M).
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